More than 50% of late breast cancer recurrences in women with ER positive/HER2 negative disease occur after 5 years’ endocrine treatment. Accurate long-term prognosis is therefore crucial to help clinicians to decide if stopping hormone therapy with their breast cancer patient is the right decision.
EndoPredict is the only test able to predict risk of recurrence up to 15 years, proven in an analysis from the randomized phase III ABCSG-6 and ABCSG-8 trials enrolling over 1,000 patients.
Fill out the form below to download your free copy of the clinical summary to learn more about this key study.